文献速递支持与姑息治疗

免疫检查点抑制剂治疗后的血液学免疫相关不良事件

Hematological immune related adverse events after treatment with immune checkpoint inhibitors.
PubMed 文献 · Eur J Cancer · 2021-03-09

该研究通过18个国际癌症中心回顾性筛选超过7626例接受ICI治疗的患者,识别出50例血液学irAE,计算发病率0.6%,中位起病时间6周。血小板减少和白细胞减少最常见(各34%),78%事件缓解,18%持续改变,2%致命。

要点

  • 血液学irAE发病率0.6%,中位起病6周,可累及所有造血细胞系。
  • 血小板减少和白细胞减少最常见(各34%),其次贫血28%。
  • 78%事件缓解,18%持续改变,2%致命(粒细胞缺乏症)。

核心结论

  • 血液学irAE可影响所有造血细胞系,可能持续甚至致命。
  • 管理可能需要超越皮质类固醇的免疫抑制治疗。
  • 尽管罕见,治疗医生应意识到并定期监测血常规,发现后及时处理。

研究设计与样本

  • 回顾性识别来自18个国际癌症中心接受ICI治疗期间发生血液学irAE的患者。
  • 共筛选超过7626例接受ICI治疗的患者,识别出50例血液学irAE患者。

主要发现

  • 计算发病率为0.6%,中位起病时间为ICI启动后6周(范围1-128周)。
  • 血小板减少和白细胞减少最常见,各占34%(17/50),其次贫血28%(14/50)。
  • 其他事件包括噬血细胞性淋巴组织细胞增生症4%(2/50)、再生障碍性贫血2%(1/50)、获得性血友病A 2%(1/50)和凝血缺陷2%(1/50)。
  • 两例患者同时发生血小板减少和中性粒细胞减少,一例同时发生贫血和血小板减少。
  • 除停用ICI(60%)和皮质类固醇(78%)外,24%的病例接受了二线免疫抑制治疗。

临床怎么用

  • 治疗医生应意识到血液学irAE,定期监测血常规,发现后及时处理。
  • 管理可能需要停用ICI、使用皮质类固醇,部分病例需二线免疫抑制治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect management for these potentially life-threatening events, we analysed frequency, severity and outcomes. PATIENTS AND METHODS: Patients who developed hem-irAE while being treated with immune checkpoint inhibitors (ICI) therapy were retrospectively identified from 18 international cancer centres. RESULTS: In total, more than 7626 patients treated with ICI were screened, and 50 patients with hem-irAE identified. The calculated incidence amounts to 0.6% and median onset was 6 weeks after the ICI initiation (range 1-128 weeks). Thrombocytopenia and leucopaenia were the most frequent hem-irAE with 34% (17/50) and 34% (17/50), respectively, followed by anaemia 28% (14/50), hemophagocytic lymphohistiocytosis (4% (2/50)), aplastic anaemia (2% (1/50)), acquired haemophilia A (2% (1/50)) and coagulation deficiency (2% (1/50)). Simultaneous thrombocytopenia and neutropenia occurred in two patients, concurrent anaemia and thrombocytopenia in one patient. Other than cessation of ICI (in 60%) and corticosteroids (in 78%), treatment included second-line immunosuppression in 24% of cases. Events resolved in 78% (39/50), while 18% (9/50) had persistent changes, and 2% (1/50) had fatal outcomes (agranulocytosis). CONCLUSION: Hem-irAE can affect all haematopoietic blood cell lineages and may persist or even be fatal. Management may require immunosuppression beyond corticosteroids. Although these irAE are rare, treating physicians should be aware, monitor blood counts regularly and promptly act upon detection.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kramer R, Zaremba A, Moreira A, et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer. 2021. PMID: 33706206. doi:10.1016/j.ejca.2021.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。